Brief: Clinuvel Pharmaceuticals Posts HY Net Profit Attributable Increased 94% To A$11.4 Mln
24/02/2023 01:21
Feb 24 (Reuters) - Clinuvel Pharmaceuticals Ltd
CUV.AX :
* HY NET PROFIT ATTRIBUTABLE INCREASED 94% TO A$11.4 MILLION
* HY REVENUES FROM ORDINARY ACTIVITIES INCREASED 19% TO
A$29.4
MILLION
Source text for Eikon: ID:nASXb5q9c5
Further company coverage: CUV.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Clinuvel Pharmaceuticals
See all newsBrief: Clinuvel Pharmaceuticals Announces Strategic Reorganisation To Refocus On U.S. Markets
Brief: Clinuvel Pharmaceuticals Ltd's ADS To Commence Trading On Nasdaq
Brief: Clinuvel Pharmaceuticals Says Scenesse Approved For EPP In Canada
Australia's Clinuvel Pharmaceuticals rises on Canada nod for phototoxicity prevention drug
Brief: Clinuvel Pharmaceuticals Updates On Level II ADR Upgrade, Nasdaq Uplist